Roche diagnostics products8/15/2023 However, group sales climbed by 1% overall at constant exchange rates to CHF 58.3bn, while Q4 sales also increased by 1% thanks to the strength of the Swiss franc. “We developed in record time a comprehensive portfolio of diagnostic solutions and entered new partnerships to develop and produce effective COVID-19 medicines,” he added.Įlsewhere in Roche’s Q4 results, the company’s pharmaceuticals division took a hit, slipping 2% in 2020 due to the continuing impact from biosimilars on key products, including its cancer treatments Herceptin (trastuzumab), Avastin (bevacizumab) and Rituxan (rituximab).Īll in all, this caused a CHF 5.1bn decrease in sales in the pharmaceuticals division over the course of 2020. “Roche continues to make important contributions to fighting the COVID-19 pandemic,” said Severin Schwan, chief executive officer of Roche. Roche launched a total of 15 tests for COVID-19 throughout 2020, including rapid tests given at the point-of-care and tests designed for clinical laboratory evaluation. The company’s molecular diagnostics products mainly fuelled that growth, thanks to Roche’s growing portfolio of COVID-19 tests, growing over 90% in 2020 at constant exchange rates. Roche’s diagnostic business revenues increased by 28% in the Swiss pharma company’s fourth quarter results, driven primarily by its COVID-19 products.įor the full year, sales in Roche’s diagnostics division grew by 14%, bringing in CHF 13.8bn in 2020 compared to CHF 12.9bn in 2019.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |